PMV Pharmaceuticals

General Information
Business:

We are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells. However, mutant p53 proteins can be misfolded and lose their wild-type tumor-suppressing function. These p53 mutations are found in approximately half of all cancers.

The field of p53 biology was established by our co-founder, Dr. Arnold Levine, when he discovered the p53 protein in 1979. We have leveraged more than four decades of research experience and developed unique insights into p53 to create a precision oncology platform designed to generate selective, small molecule, tumor-agnostic therapies that structurally correct specific mutant p53 proteins to restore their wild-type function. We are deploying our precision oncology platform to target the top 10 most frequent, or hotspot, p53 mutations that are collectively associated with approximately 10% to 15% of all cancers.

We believe that we have designed our lead product candidate, PC14586, to potently and selectively correct p53 misfolding caused by a specific p53 mutation, Y220C, while sparing wild-type p53. The Y220C mutation is associated with 1.0%  to 1.5% of all cancers, including breast, non-small cell lung cancer, or NSCLC, colorectal, pancreatic and ovarian cancers.

Industry: Pharmaceuticals
Employees: 39
Founded: 2013
Contact Information
Address 8 Clarke Drive, Suite 3 Cranbury, NJ 08512
Phone Number (609) 642-6670
Web Address http://www.pmvpharma.com
View Prospectus: PMV Pharmaceuticals
Financial Information
Market Cap $655.86mil
Revenues $0 mil (last 12 months)
Net Income $-40.6 mil (last 12 months)
IPO Profile
Symbol PMVP
Exchange NASDAQ
Shares (millions): 11.8
Price range $18.00 - $18.00
Est. $ Volume $211.7 mil
Manager / Joint Managers Goldman Sachs/ BofA Securities/ Cowen/ Evercore ISI
CO-Managers
Expected To Trade: 9/25/2020
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change